Close Menu

familial adenomatous polyposis

Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.

Investigators identified mutation, expression, and methylation differences in colorectal polyps from individuals with or without colorectal cancer.

Researchers identified two cases with biallelic mutations in MSH3 in exome sequences from more than 100 patients with unexplained colorectal adenomatous polyposis.

In individuals at risk of colorectal cancer, pre-cancerous adenomas contain somatic mutations affecting known cancer genes and pathways.

Restarting the trial will require the company to raise additional funds before its money runs out this summer.

With a portfolio of more mature technologies and increased interest in RNAi from the investment and pharmaceutical communities alike, Marina Biotech expects to rebuild itself as a leaner company with a greater focus on drug discovery, the struggling company’s top official said th

While RNAi drug developers continue to pursue major indications such as cancer and hepatitis C, a number of these companies are looking to niche diseases as good opportunities to apply the gene-silencing technology.

By Doug Macron
Marina Biotech this week announced that it will shortly begin enrolling the second cohort of patients in an ongoing phase Ib/IIa trial of its RNAi-based familial adenomatous polyposis treatment CEQ508.

The drug uses orally delivered attenuated Escherichia coli to transcribe shRNAs targeting beta-catenin, an oncogene that plays a role in the development of colorectal polyps that characterize the disease.

The move marks the company's foray into the ranks of clinical-stage drug developers and its first steps toward becoming a therapeutics marketer.

Pages

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.